Outlook Therapeutics appoints new board chair  

Iselin-based Outlook Therapeutics a biopharmaceutical company based in Iselin on Friday announced it appointed Faisal Sukhtian as chairman of the board of directors, effective immediately. MSukhtian will assume the role from Randy Thurman, who will remain on the board as Lead Independent Director.

“On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude to Randy for his extraordinary leadership and unwavering commitment. Under his guidance, Outlook Therapeutics has evolved from a preclinical biotech to a company preparing to launch our first product,” Sukhtian said. “Randy’s decades of experience in the biopharmaceutical industry, strategic insight, and mentorship have been invaluable in shaping the Company’s trajectory. I am personally grateful for his continued role as Lead Independent Director, and I look forward to continuing to work closely with him as we embark on this exciting next phase.”

“I look forward to continuing as a member of the Outlook Therapeutics Board as Lead Independent Director and working toward our goal of getting LYTENAVA™ approved and launched worldwide,” Thurman said. “Were it not for Faisal and GMS Ventures and Investments, and their financial leadership, Outlook Therapeutics would not be where it is today – on the verge of an opportunity to greatly improve the health of patients around the world suffering from neovascular age-related macular degeneration. Improving human health has been the focus of my long career in life sciences.”

Sukhtian has served as a member of Outlook Therapeutics’ Board of Directors since 2017.

Over the course of his career, he has amassed extensive experience in operations, strategy development and mergers and acquisitions in the biopharma and life sciences space.

He currently serves as Executive Director at GMS Holdings and oversees a number of investments within the GMS Holdings portfolio.

Sukhtian also serves as the chairman of the Board of Genepharm, a leading European B2B pharmaceutical company; as a member of the Board of MS Pharma, a leading regional pharmaceutical company focused on the MENA region; as vice chairman of the Board of Agri Sciences, an international crop protection company headquartered in Jordan and Turkey; and as a member of the Board of Expert Petroleum, an oilfield services company based in Romania.